Bristol Myers' New Treatments Drive Q3 Beat — And The Company's Raising Its Outlook

Bristol Myers Squibb Co. (NYSE:BMY) reported third-quarter 2025 revenues of $12.22 billion on Thursday, beating the consensus of $11.81 billion, a 3% increase year over year.Growth Portfolio revenues of $6.9 billion increased 18%, or 17% Ex-FX. Revenue growth was primarily driven by the immuno-oncology portfolio, Reblozyl, Camzyos, and Breyanzi.Also Read: Bristol Myers Expands Cell Therapy Portfolio With Orbital Therapeutics AcquisitionLegacy Portfolio revenues of $5.4 billion decreased 12%, or 13% Ex-FX. D ...